Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Prepaid Assets: 2009-2025

Historic Prepaid Assets for Ani Pharmaceuticals (ANIP) over the last 17 years, with Sep 2025 value amounting to $18.6 million.

  • Ani Pharmaceuticals' Prepaid Assets rose 6.16% to $18.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.6 million, marking a year-over-year increase of 6.16%. This contributed to the annual value of $18.0 million for FY2024, which is 3.30% up from last year.
  • As of Q3 2025, Ani Pharmaceuticals' Prepaid Assets stood at $18.6 million, which was up 22.77% from $15.1 million recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Prepaid Assets high stood at $23.3 million for Q1 2025, and its period low was $4.7 million during Q3 2021.
  • For the 3-year period, Ani Pharmaceuticals' Prepaid Assets averaged around $15.1 million, with its median value being $16.1 million (2024).
  • As far as peak fluctuations go, Ani Pharmaceuticals' Prepaid Assets decreased by 11.03% in 2023, and later skyrocketed by 133.49% in 2024.
  • Ani Pharmaceuticals' Prepaid Assets (Quarterly) stood at $7.6 million in 2021, then climbed by 10.52% to $8.4 million in 2022, then soared by 107.46% to $17.4 million in 2023, then climbed by 3.30% to $18.0 million in 2024, then climbed by 6.16% to $18.6 million in 2025.
  • Its last three reported values are $18.6 million in Q3 2025, $15.1 million for Q2 2025, and $23.3 million during Q1 2025.